Elsie’s discovery platform accesses the entire oligonucleotide chemistry space to optimize current modalities in gene silencing and splice switching, and applies proprietary chemistry technologies to develop novel, diverse oligonucleotide therapeutics that are designed to be more potent, safer, and easier to deliver to target tissues.